Morgan Stanley initiates coverage on Immix Biopharma with Overweight rating, $20 PT.

miércoles, 25 de marzo de 2026, 10:19 am ET1 min de lectura
IMMX--

Morgan Stanley initiates coverage on Immix Biopharma with Overweight rating, $20 PT.

Morgan Stanley initiates coverage on Immix Biopharma with Overweight rating, $20 PT.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios